Keros Therapeutics, Inc.(KROS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Keros Therapeutics, Inc. (KROS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KROS at 27.3/100 on a 32-signal composite quality model, placing it at rank #2,586 of 2,962 stocks — the bottom half of the AI-ranked universe. KROS scores in the top quartile across revenue growth (99.3). Areas of concern include revenue scale (2.9) and profitability (3.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Keros Therapeutics, Inc. reports net income of $-28.7M, free cash flow of $-20.6M. Top institutional holders of KROS by reported 13-F value include BlackRock, Nantahala Capital Management, AQR CAPITAL MANAGEMENT, based on the most recent SEC filings. KROS trades on the Nasdaq exchange and files with the SEC under CIK 1664710. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KROS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Keros Therapeutics, Inc. directly from SEC EDGAR.